Europe's Clinical AI Market Faces a Reckoning as U.S. Platforms Pull Back

When OpenEvidence announced in April 2026 that it would terminate access for clinicians in the United Kingdom and European Union, the reaction from European physicians was swift and vocal. Thousands of doctors who had integrated the AI-powered medical search tool into their daily clinical practice suddenly found themselves without access to a resource they had come to rely on. The company cited the complexity of complying with GDPR, the EU AI Act, and the UK's emerging AI regulatory framework as factors in the decision.^[1]

The episode is not an isolated business decision. It is a symptom of a structural problem that has been building in European healthcare AI for years: the continent's clinicians and health systems have become increasingly dependent on AI tools developed and operated by U.S. companies, without building equivalent domestic capabilities or establishing the regulatory frameworks that would make it attractive for U.S. companies to serve European markets.

The Regulatory Divergence

The EU AI Act, which came into force in stages beginning in 2024, classifies most clinical AI tools as high-risk AI systems subject to extensive conformity assessment requirements, technical documentation obligations, and post-market monitoring mandates. The UK's AI regulatory approach, while less prescriptive than the EU's, adds another layer of jurisdiction-specific compliance for companies that want to serve both markets. For a U.S. company whose primary market is the 860,000 U.S. clinicians it already serves, the cost-benefit calculation of maintaining EU and UK compliance may simply not pencil out — particularly when the European market represents a small fraction of total users.^[2]